{"transactions":[{"id":672977,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-28T21:40:02.000Z","date":"2026-08-27","kind":"exercise","planned":false,"acquired":false,"shares":27052,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.63,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":27052},"source":{"system":"sec-edgar","filing":"0001628280-26-059444","document":"wk-form4_1787953199.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026059444/wk-form4_1787953199.xml","form_type":"4"}},{"id":672976,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-28T21:40:02.000Z","date":"2026-08-27","kind":"exercise","planned":false,"acquired":false,"shares":11148,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.51,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":11148},"source":{"system":"sec-edgar","filing":"0001628280-26-059444","document":"wk-form4_1787953199.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026059444/wk-form4_1787953199.xml","form_type":"4"}},{"id":672975,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T21:40:02.000Z","date":"2026-08-27","kind":"sale","planned":false,"acquired":false,"shares":27052,"price":25.0294,"value":677095.3288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":23526,"source":{"system":"sec-edgar","filing":"0001628280-26-059444","document":"wk-form4_1787953199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026059444/wk-form4_1787953199.xml","form_type":"4"}},{"id":672974,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T21:40:02.000Z","date":"2026-08-27","kind":"exercise","planned":false,"acquired":true,"shares":27052,"price":8.63,"value":233458.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service."}],"balance_after":50578,"source":{"system":"sec-edgar","filing":"0001628280-26-059444","document":"wk-form4_1787953199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026059444/wk-form4_1787953199.xml","form_type":"4"}},{"id":672973,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T21:40:02.000Z","date":"2026-08-27","kind":"sale","planned":false,"acquired":false,"shares":11148,"price":25.0294,"value":279027.7512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":23526,"source":{"system":"sec-edgar","filing":"0001628280-26-059444","document":"wk-form4_1787953199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026059444/wk-form4_1787953199.xml","form_type":"4"}},{"id":672972,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T21:40:02.000Z","date":"2026-08-27","kind":"exercise","planned":false,"acquired":true,"shares":11148,"price":7.51,"value":83721.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service."}],"balance_after":34674,"source":{"system":"sec-edgar","filing":"0001628280-26-059444","document":"wk-form4_1787953199.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026059444/wk-form4_1787953199.xml","form_type":"4"}},{"id":677402,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-24T20:19:44.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":false,"shares":1072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested."}],"balance_after":11148,"derivative":{"exercise_price":7.51,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":1072},"source":{"system":"sec-edgar","filing":"0001628280-26-058648","document":"wk-form4_1787602781.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026058648/wk-form4_1787602781.xml","form_type":"4"}},{"id":677401,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T20:19:44.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":1072,"price":26.0376,"value":27912.3072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":23526,"source":{"system":"sec-edgar","filing":"0001628280-26-058648","document":"wk-form4_1787602781.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026058648/wk-form4_1787602781.xml","form_type":"4"}},{"id":677400,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T20:19:44.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":true,"shares":1072,"price":7.51,"value":8050.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service."}],"balance_after":24598,"source":{"system":"sec-edgar","filing":"0001628280-26-058648","document":"wk-form4_1787602781.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026058648/wk-form4_1787602781.xml","form_type":"4"}},{"id":744684,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-10T01:21:08.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date."}],"balance_after":16667,"derivative":{"exercise_price":21.23,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001628280-26-042042","document":"wk-form4_1781054465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026042042/wk-form4_1781054465.xml","form_type":"4"}},{"id":744683,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-10T01:21:08.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":5778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 22, 2025, maintained by the Company."}],"balance_after":23526,"source":{"system":"sec-edgar","filing":"0001628280-26-042042","document":"wk-form4_1781054465.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000162828026042042/wk-form4_1781054465.xml","form_type":"4"}},{"id":1109805,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-17T00:17:27.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date."}],"balance_after":20568,"derivative":{"exercise_price":13.5,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20568},"source":{"system":"sec-edgar","filing":"0002065881-25-000025","document":"wk-form4_1750119440.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000206588125000025/wk-form4_1750119440.xml","form_type":"4"}},{"id":1109804,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T00:17:27.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":7609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 16, 2024, maintained by the Company."}],"balance_after":17748,"source":{"system":"sec-edgar","filing":"0002065881-25-000025","document":"wk-form4_1750119440.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000206588125000025/wk-form4_1750119440.xml","form_type":"4"}},{"id":1235875,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T22:16:33.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":342500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":342500,"derivative":{"exercise_price":5.76,"expiration_date":"2035-02-26","underlying":"Common Stock","underlying_shares":342500},"source":{"system":"sec-edgar","filing":"0000950170-25-031048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000095017025031048/ownership.xml","form_type":"4"}},{"id":1296405,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2025-01-23T21:19:11.000Z","date":"2025-01-21","kind":"sale","planned":false,"acquired":false,"shares":19109,"price":6.5877,"value":125884.3593,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6503. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,840 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025."}],"balance_after":360465,"source":{"system":"sec-edgar","filing":"0000950170-25-008348","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000095017025008348/ownership.xml","form_type":"4"}},{"id":1366607,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T23:45:09.000Z","date":"2024-11-11","kind":"sale","planned":false,"acquired":false,"shares":8687,"price":10.8482,"value":94238.3134,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $10.7542 to $10.97, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":10139,"source":{"system":"sec-edgar","filing":"0001787306-24-000155","document":"wk-form4_1731541502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000178730624000155/wk-form4_1731541502.xml","form_type":"4"}},{"id":1452612,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2024-07-17T18:50:07.000Z","date":"2024-07-15","kind":"sale","planned":false,"acquired":false,"shares":33848,"price":11.72,"value":396698.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 798 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2024."}],"balance_after":377734,"source":{"system":"sec-edgar","filing":"0000950170-24-084179","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000095017024084179/ownership.xml","form_type":"4"}},{"id":1475390,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T20:52:04.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":27052,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service."}],"balance_after":27052,"derivative":{"exercise_price":8.63,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":27052},"source":{"system":"sec-edgar","filing":"0001787306-24-000103","document":"wk-form4_1718743917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000178730624000103/wk-form4_1718743917.xml","form_type":"4"}},{"id":1475389,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-18T20:52:04.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":10139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders.  The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.  The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."}],"balance_after":18826,"source":{"system":"sec-edgar","filing":"0001787306-24-000103","document":"wk-form4_1718743917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000178730624000103/wk-form4_1718743917.xml","form_type":"4"}},{"id":1560602,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2024-03-26T20:05:11.000Z","date":"2024-03-22","kind":"sale","planned":false,"acquired":false,"shares":16851,"price":9.11,"value":153512.61,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.11 to $9.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,604 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024."}],"balance_after":410784,"source":{"system":"sec-edgar","filing":"0000950170-24-036398","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000095017024036398/ownership.xml","form_type":"4"}},{"id":1674216,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-23T01:19:27.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":475000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":475000,"derivative":{"exercise_price":7.6,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":475000},"source":{"system":"sec-edgar","filing":"0001209191-24-002019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919124002019/doc4.xml","form_type":"4"}},{"id":1749837,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2023-11-03T20:53:21.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned with respect to performance stock unit awards granted on July 1, 2020 and January 19, 2023 that contained a performance-vesting requirement that was satisfied on November 1, 2023."}],"balance_after":427171,"source":{"system":"sec-edgar","filing":"0001209191-23-054346","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123054346/doc4.xml","form_type":"4"}},{"id":1828725,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option","published_at":"2023-07-17T21:00:14.000Z","date":"2023-07-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":0,"derivative":{"exercise_price":39.11,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001209191-23-042454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123042454/doc4.xml","form_type":"4"}},{"id":1828724,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option","published_at":"2023-07-17T21:00:14.000Z","date":"2023-07-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":175000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":0,"derivative":{"exercise_price":32.2,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-23-042454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123042454/doc4.xml","form_type":"4"}},{"id":1828723,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2023-07-17T21:00:14.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 400,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 200,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,381 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023."}],"balance_after":389671,"source":{"system":"sec-edgar","filing":"0001209191-23-042454","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123042454/doc4.xml","form_type":"4"}},{"id":1869989,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T23:10:55.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":12220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023."}],"balance_after":12220,"derivative":{"exercise_price":7.51,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":12220},"source":{"system":"sec-edgar","filing":"0001787306-23-000058","document":"wk-form4_1685747445.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000178730623000058/wk-form4_1685747445.xml","form_type":"4"}},{"id":1869988,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T23:10:55.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":8687,"source":{"system":"sec-edgar","filing":"0001787306-23-000058","document":"wk-form4_1685747445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000178730623000058/wk-form4_1685747445.xml","form_type":"4"}},{"id":1922975,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2023-04-07T19:19:51.000Z","date":"2023-04-06","kind":"purchase","planned":false,"acquired":true,"shares":12919,"price":7.8199,"value":101025.2881,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.79 to $7.85. The Reporting Person undertakes to provide Phathom Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":188290,"source":{"system":"sec-edgar","filing":"0001209191-23-023751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123023751/doc4.xml","form_type":"4"}},{"id":1958804,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T14:27:33.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":21096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":22.71,"expiration_date":"2031-11-04","underlying":"Common Shares","underlying_shares":21096},"source":{"system":"sec-edgar","filing":"0001209191-23-017716","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123017716/doc4.xml","form_type":"4"}},{"id":1958803,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T14:27:33.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":21603,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":21.47,"expiration_date":"2030-09-14","underlying":"Common Shares","underlying_shares":21603},"source":{"system":"sec-edgar","filing":"0001209191-23-017716","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123017716/doc4.xml","form_type":"4"}},{"id":1958802,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T14:27:33.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":5250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.65,"expiration_date":"2029-08-22","underlying":"Common Shares","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001209191-23-017716","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123017716/doc4.xml","form_type":"4"}},{"id":1958801,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T14:27:33.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":24.25,"expiration_date":"2028-08-30","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-23-017716","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123017716/doc4.xml","form_type":"4"}},{"id":1958800,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T14:27:33.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.14,"expiration_date":"2027-08-17","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-23-017716","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123017716/doc4.xml","form_type":"4"}},{"id":1958799,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T14:27:33.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":11154,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.68,"expiration_date":"2027-05-14","underlying":"Common Shares","underlying_shares":11154},"source":{"system":"sec-edgar","filing":"0001209191-23-017716","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123017716/doc4.xml","form_type":"4"}},{"id":1958798,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T14:27:33.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":33846,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":11.3,"expiration_date":"2026-11-14","underlying":"Common Shares","underlying_shares":33846},"source":{"system":"sec-edgar","filing":"0001209191-23-017716","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123017716/doc4.xml","form_type":"4"}},{"id":1958797,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-03-10T14:27:33.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":3673,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the vested portion of 9,859 restricted stock units (\"RSUs\") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the \"Effective Time\") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the \"Per Share Consideration\"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the \"RSU Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-017716","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123017716/doc4.xml","form_type":"4"}},{"id":1973781,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2023-03-03T23:59:14.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":1436,"price":8.5411,"value":12265.0196,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.53 to $8.7614. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":175371,"source":{"system":"sec-edgar","filing":"0001209191-23-016002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123016002/doc4.xml","form_type":"4"}},{"id":2049703,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-21T00:39:46.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":162500,"derivative":{"exercise_price":8.35,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":162500},"source":{"system":"sec-edgar","filing":"0001209191-23-004341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123004341/doc4.xml","form_type":"4"}},{"id":2049702,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2023-01-21T00:39:46.000Z","date":"2023-01-20","kind":"sale","acquired":false,"shares":5821,"price":8.1995,"value":47729.2895,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.16 to $8.20. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":176807,"source":{"system":"sec-edgar","filing":"0001209191-23-004341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123004341/doc4.xml","form_type":"4"}},{"id":2049701,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2023-01-21T00:39:46.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":97500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,408 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023."}],"balance_after":182628,"source":{"system":"sec-edgar","filing":"0001209191-23-004341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919123004341/doc4.xml","form_type":"4"}},{"id":2105287,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2022-11-23T21:07:34.000Z","date":"2022-11-21","kind":"sale","acquired":false,"shares":1526,"price":9.6,"value":14649.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.59 to $9.90. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":83720,"source":{"system":"sec-edgar","filing":"0001209191-22-058619","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919122058619/doc4.xml","form_type":"4"}},{"id":2130393,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-10-28T20:45:16.000Z","date":"2022-10-26","kind":"grant","acquired":true,"shares":9859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person as the annual non-employee director grant.  The RSUs shall (x) vest in full on the earlier to occur of (i) October 26, 2023 and (ii) the date that is one day prior to the Issuer's 2023 annual shareholder meeting, subject in each case to the Reporting Person providing continuous service to the Issuer on such date, or (y) to the extent the RSUs have not vested as of the Effective Time, vest pro rata based on the number of days the Reporting Person has served since October 26, 2022 (by using 365 days for a full year), and the vested RSUs shall be entitled to the RSU Consideration as set forth in Section 2.04(b)(i) of the Merger Agreement, and the unvested RSUs shall be forfeited without consideration as of the Effective Time."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each capitalized term not defined above has the meaning assigned to it in that certain Agreement and Plan of Merger by and among the Issuer, Sumitovant Biopharma Ltd., Zeus Sciences Ltd., and, solely with respect to Article IX and Annex A, Sumitomo Pharma Co., Ltd. dated October 23, 2022 (the \"Merger Agreement\")."}],"balance_after":9859,"source":{"system":"sec-edgar","filing":"0001209191-22-054817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919122054817/doc4.xml","form_type":"4"}},{"id":2167666,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2022-09-02T20:05:35.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,151 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022."}],"balance_after":85246,"source":{"system":"sec-edgar","filing":"0001209191-22-048472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919122048472/doc4.xml","form_type":"4"}},{"id":2244836,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:58:28.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":11796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022."}],"balance_after":11796,"derivative":{"exercise_price":20.29,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":11796},"source":{"system":"sec-edgar","filing":"0001567619-22-012323","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000156761922012323/doc1.xml","form_type":"4"}},{"id":2244835,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-03T20:58:28.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":4312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,312 Restricted Stock Units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":4312,"source":{"system":"sec-edgar","filing":"0001567619-22-012323","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000156761922012323/doc1.xml","form_type":"4"}},{"id":2261888,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2022-05-20T21:14:33.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on May 19, 2022. One third (1/3) of the total number of RSUs granted vest on November 19, 2022, May 19, 2023 and November 19, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":76595,"source":{"system":"sec-edgar","filing":"0001209191-22-031080","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919122031080/doc4.xml","form_type":"4"}},{"id":2270405,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2022-05-17T00:45:38.000Z","date":"2022-05-13","kind":"purchase","acquired":true,"shares":20500,"price":7.4066,"value":151835.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.28 to $7.56. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":64595,"source":{"system":"sec-edgar","filing":"0001209191-22-029451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919122029451/doc4.xml","form_type":"4"}},{"id":2428775,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-21T23:47:40.000Z","date":"2022-01-19","kind":"grant","acquired":true,"shares":206250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":206250,"derivative":{"exercise_price":15.21,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":206250},"source":{"system":"sec-edgar","filing":"0001209191-22-004488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919122004488/doc4.xml","form_type":"4"}},{"id":2428774,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2022-01-21T23:47:40.000Z","date":"2022-01-19","kind":"grant","acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,705 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2021, July 2021 and January 2022."}],"balance_after":44095,"source":{"system":"sec-edgar","filing":"0001209191-22-004488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919122004488/doc4.xml","form_type":"4"}},{"id":2519677,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-09T22:40:07.000Z","date":"2021-11-05","kind":"grant","acquired":true,"shares":21096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest and become exercisable on the earlier of (a) November 5, 2022, and (b) the date that is one day prior to the Issuer's 2022 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date."}],"balance_after":21096,"derivative":{"exercise_price":22.71,"expiration_date":"2031-11-04","underlying":"Common Shares","underlying_shares":21096},"source":{"system":"sec-edgar","filing":"0001209191-21-063678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121063678/doc4.xml","form_type":"4"}},{"id":2571990,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-13T20:11:39.000Z","date":"2021-09-09","kind":"exercise","acquired":false,"shares":4850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested."}],"balance_after":5250,"derivative":{"exercise_price":7.65,"expiration_date":"2029-08-23","underlying":"Common Shares","underlying_shares":4850},"source":{"system":"sec-edgar","filing":"0001209191-21-055667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121055667/doc4.xml","form_type":"4"}},{"id":2571989,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-09-13T20:11:39.000Z","date":"2021-09-09","kind":"sale","acquired":false,"shares":4850,"price":25.58,"value":124063.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $25.42 to $25.72. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-055667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121055667/doc4.xml","form_type":"4"}},{"id":2571988,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-09-13T20:11:39.000Z","date":"2021-09-09","kind":"exercise","acquired":true,"shares":4850,"price":7.65,"value":37102.5,"ownership":{"direct":true},"balance_after":4850,"source":{"system":"sec-edgar","filing":"0001209191-21-055667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121055667/doc4.xml","form_type":"4"}},{"id":2579311,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T20:25:06.000Z","date":"2021-09-02","kind":"exercise","acquired":false,"shares":37135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":10100,"derivative":{"exercise_price":7.65,"expiration_date":"2029-08-23","underlying":"Common Shares","underlying_shares":37135},"source":{"system":"sec-edgar","filing":"0001209191-21-054758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121054758/doc4.xml","form_type":"4"}},{"id":2579310,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T20:25:06.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":11373,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Fully vested."}],"balance_after":47235,"derivative":{"exercise_price":7.65,"expiration_date":"2029-08-23","underlying":"Common Shares","underlying_shares":11373},"source":{"system":"sec-edgar","filing":"0001209191-21-054758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121054758/doc4.xml","form_type":"4"}},{"id":2579309,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-09-03T20:25:06.000Z","date":"2021-09-02","kind":"sale","acquired":false,"shares":37135,"price":25.03,"value":929489.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold at prices ranging from $25.00 to $25.10. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-054758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121054758/doc4.xml","form_type":"4"}},{"id":2579308,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-09-03T20:25:06.000Z","date":"2021-09-02","kind":"exercise","acquired":true,"shares":37135,"price":7.65,"value":284082.75,"ownership":{"direct":true},"balance_after":37135,"source":{"system":"sec-edgar","filing":"0001209191-21-054758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121054758/doc4.xml","form_type":"4"}},{"id":2579307,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-09-03T20:25:06.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":11373,"price":25,"value":284325.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to a 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $25.00 to $25.01. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-054758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121054758/doc4.xml","form_type":"4"}},{"id":2579306,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2021-09-03T20:25:06.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":11373,"price":7.65,"value":87003.45,"ownership":{"direct":true},"balance_after":11373,"source":{"system":"sec-edgar","filing":"0001209191-21-054758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121054758/doc4.xml","form_type":"4"}},{"id":2672054,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-11T20:36:09.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":13391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":13391,"derivative":{"exercise_price":27.77,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":13391},"source":{"system":"sec-edgar","filing":"0001567619-21-012026","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000156761921012026/doc1.xml","form_type":"4"}},{"id":2774882,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-23T23:22:06.000Z","date":"2021-03-22","kind":"exercise","acquired":false,"shares":11513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option was granted on August 29, 2019 and vested with respect to 25% of the shares of common stock on August 29, 2020, and thereafter vests in equal monthly installments over the following three years."}],"balance_after":855687,"derivative":{"exercise_price":6.95,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":11513},"source":{"system":"sec-edgar","filing":"0001209191-21-022705","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121022705/doc4.xml","form_type":"4"}},{"id":2774881,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2021-03-23T23:22:06.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":1140,"price":44.0838,"value":50255.532,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.71. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-022705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121022705/doc4.xml","form_type":"4"}},{"id":2774880,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2021-03-23T23:22:06.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":10373,"price":43.2368,"value":448495.3264,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.82 to $43.81. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1140,"source":{"system":"sec-edgar","filing":"0001209191-21-022705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121022705/doc4.xml","form_type":"4"}},{"id":2774879,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2021-03-23T23:22:06.000Z","date":"2021-03-22","kind":"exercise","acquired":true,"shares":11513,"price":6.95,"value":80015.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received upon exercising a stock option."}],"balance_after":11513,"source":{"system":"sec-edgar","filing":"0001209191-21-022705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121022705/doc4.xml","form_type":"4"}},{"id":2890413,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-29T21:27:23.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":225000,"derivative":{"exercise_price":39.11,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001209191-21-006094","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919121006094/doc4.xml","form_type":"4"}},{"id":2992886,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-04T21:34:26.000Z","date":"2020-11-02","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/3 of the total shares on each of November 2, 2021, November 2, 2022 and November 2, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":37500,"derivative":{"exercise_price":18.72,"expiration_date":"2030-11-02","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001567619-20-018694","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000156761920018694/doc1.xml","form_type":"4"}},{"id":3028605,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-17T20:16:55.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":21603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date."}],"balance_after":21603,"derivative":{"exercise_price":21.47,"expiration_date":"2030-09-14","underlying":"Common Shares","underlying_shares":21603},"source":{"system":"sec-edgar","filing":"0001209191-20-050882","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919120050882/doc4.xml","form_type":"4"}},{"id":3092072,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T20:44:08.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to 25% of the shares of common stock on July 1, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":175000,"derivative":{"exercise_price":32.2,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-20-040392","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690298/000120919120040392/doc4.xml","form_type":"4"}},{"id":3362074,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:21.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":27749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":27749},"source":{"system":"sec-edgar","filing":"0001415889-19-001376","document":"form4-11222019_071108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001376/form4-11222019_071108.xml","form_type":"4"}},{"id":3362073,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:21.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":4120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4120},"source":{"system":"sec-edgar","filing":"0001415889-19-001376","document":"form4-11222019_071108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001376/form4-11222019_071108.xml","form_type":"4"}},{"id":3362072,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:21.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6593},"source":{"system":"sec-edgar","filing":"0001415889-19-001376","document":"form4-11222019_071108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001376/form4-11222019_071108.xml","form_type":"4"}},{"id":3362071,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:21.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":1857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1857},"source":{"system":"sec-edgar","filing":"0001415889-19-001376","document":"form4-11222019_071108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001376/form4-11222019_071108.xml","form_type":"4"}},{"id":3362070,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:31:21.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3426},"source":{"system":"sec-edgar","filing":"0001415889-19-001376","document":"form4-11222019_071108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001376/form4-11222019_071108.xml","form_type":"4"}},{"id":3362200,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":12983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":71.43,"expiration_date":"2028-10-29","underlying":"Common Stock","underlying_shares":12983},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362199,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":12983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":88.91,"expiration_date":"2028-07-30","underlying":"Common Stock","underlying_shares":12983},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362198,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":12982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":83.13,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":12982},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362197,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":103.26,"expiration_date":"2028-01-29","underlying":"Common Stock","underlying_shares":6777},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362196,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":15659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":100.97,"expiration_date":"2027-10-30","underlying":"Common Stock","underlying_shares":15659},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362195,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":135.41,"expiration_date":"2027-07-31","underlying":"Common Stock","underlying_shares":6776},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362194,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":124.06,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":6776},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362193,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":113.18,"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":6563},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362192,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":6562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":102.18,"expiration_date":"2026-10-31","underlying":"Common Stock","underlying_shares":6562},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362191,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":114.69,"expiration_date":"2026-08-01","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362190,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":104.97,"expiration_date":"2026-05-02","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362189,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":100.8,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362188,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":114.08,"expiration_date":"2025-11-09","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362187,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":132.56,"expiration_date":"2025-07-27","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362186,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":109.9,"expiration_date":"2025-05-04","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362185,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":118.57,"expiration_date":"2025-02-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362184,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":7050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":117.18,"expiration_date":"2024-12-19","underlying":"Common Stock","underlying_shares":7050},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362183,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":103.1,"expiration_date":"2024-10-27","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362182,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":87.64,"expiration_date":"2024-07-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362181,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":81.56,"expiration_date":"2023-12-02","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362180,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":58.33,"expiration_date":"2023-05-01","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362179,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":327,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"401(k) Plan"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition in connection with the Merger Agreement.  Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362178,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":37181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition in connection with the Merger Agreement.  Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362177,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":17840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":37181,"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362176,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":9889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":19341,"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3362175,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES., GLBL INFLAM. AND IMMUN."}}],"security":"Common Stock","published_at":"2019-11-22T07:31:17.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":5139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.  These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the \"Effective Time\").  In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights (\"CVRs\") in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":9452,"source":{"system":"sec-edgar","filing":"0001415889-19-001375","document":"form4-11222019_071104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001375/form4-11222019_071104.xml","form_type":"4"}},{"id":3382715,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":18725,"kind":"person","name":"Curran Terrie","position":1,"cik":"0001690298","reported_name":"Curran Terrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Restricted Stock Unit","published_at":"2019-11-04T16:05:23.000Z","date":"2019-10-31","kind":"exercise","acquired":false,"shares":3281,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3281},"source":{"system":"sec-edgar","filing":"0001415889-19-001256","document":"form4-11042019_041110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001256/form4-11042019_041110.xml","form_type":"4"}}],"next_cursor":"2019-11-04T16:05:23.000000Z,3382715"}